Thiazolidinediones (also known as glitazones or TZDs) were first used to treat type 2 diabetes in the late 1990s. TZD’s are unique in that they exert their effect by reducing insulin resistance and its action in muscle, adipose, and hepatic tissue. Mode of Action
Glitazones bind to PPAR-γ nuclear receptors, resulting in metabolic and vascular effects. These include lipid and glucose regulation, and changes to vascular function, thrombotic function, and the inflammatory response.